Skip to content
etf.net

Launched · SEC filings

VanEck Biotech ETF

BBHNasdaqVanEckB

$254.50−3.48 (−1.35%)

At close: Nov 2, 2026, 4:00 PM ET

B68/ 100

Rank 5 of 17 in Biotech & Genomics

B68/100Rank 5 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 257.98 to 254.50. Range 254.35 to 259.02. Use the arrow keys to read each point.256.00257.00259.0010 AM12 PM2 PM4 PM
Expense ratio
0.35%
Fund size
$525M
1Y total return
+43.1%
Yield · Last 12 months
0.37%
Holdings
26
Avg volume · 30D
9.55K sh
52W range
low $177.35high $262.60
Launched
Filings
SEC EDGAR

The ETF.net BBH Grade

Based on 5 of 6 pillars

B

Score 68 out of 100

Category
Biotech & Genomics⁠
Rank
5 of 17
Six-pillar profile for BBH. Scores out of 100: Cost 81, Risk 68, Mission not scored, Tradability 73, Holdings 27, Durability 71. Strongest: Cost (81). Weakest: Holdings (27). Based on 5 of 6 pillars.

Score 68 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A81 out of 100
    Rank 3 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B68 out of 100
    Rank 6 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    A73 out of 100
    Rank 5 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D27 out of 100
    Rank 17 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    A71 out of 100
    Rank 6 of 17

Our read on BBH

ETF.net Research

In short

BBiotech, distilled. BBH tracks an index of around 25 US-listed drug and diagnostics companies, so each name carries real weight instead of getting lost in a crowd. Running since 2011, at a fee below the typical biotech fund.

Stated mandate

The fund seeks to track, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index. That index represents companies involved in developing, producing, marketing, and selling drugs based on genetic analysis and diagnostic equipment.

Why people hold it

  • 0.35% a year, below the 0.50% typical for biotech funds and level with XBI.
  • Around 25 holdings, so the leaders in the index actually move the fund rather than getting diluted across hundreds of tickers.
  • Rules-based: it follows the MVIS US Listed Biotech 25 Index, no manager guessing which drug pipeline pans out.vaneck.com
  • Trading since 2011, through several full biotech cycles, and it sits in the upper half of its biotech peer group.

Worth knowing

  • Concentration cuts both ways: with roughly 25 names, one failed trial or patent cliff lands hard.
  • One of the less-traded funds in the biotech aisle, so bid-ask spreads deserve attention. Limit orders are the usual fix.
  • Not the cheapest seat in the category: IBBQ charges 0.19%.

BBH Holdings

Holdings pillarD27 out of 100Rank 17 of 17 in Biotech & Genomics
Asset class
Stocks
Holdings
26
Top-10 weight
73%
Largest holding
AMGN16.4%

Sectors

  • Health Care99.9%
  • Energy0.1%

Geography

  • United States100.00%
The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueHeld by ETFs
1AMGNAmgen Inc16.42%186,331$85.8M503
2GILDGilead Sciences Inc13.94%440,111$72.9M494
3VRTXVertex Pharmaceuticals Inc8.08%78,229$42.2M429
4REGNRegeneron Pharmaceuticals Inc6.68%42,662$34.9M422
5MRNAModerna Inc6.68%156,691$34.9M297
6NTRANatera Inc4.95%59,298$25.9M239
7IQVIqvia Holdings Inc4.35%82,688$22.7M295
8ARGXArgenx Se4.09%23,816$21.4M75
9ILMNIllumina Inc4.08%73,543$21.3M331
10RVMDRevolution Medicines Inc3.72%102,316$19.5M179
11GHGuardant Health Inc2.98%83,984$15.6M183
12BIIBBiogen Inc2.88%60,213$15M332
13ONCBeone Medicines Ltd2.67%37,510$13.9M39
14UTHRUnited Therapeutics Corp2.34%20,578$12.2M270
15INCYIncyte Corp2.04%91,354$10.7M376

Showing 1–15 of 26 holdings

BBH Performance

Launched Dec 20, 2011

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

BBH$14,313
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. BBH $14,313. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000$14,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBH. Periods over one year show the average yearly return.
PeriodBBH
Year to date+36.3%
1 month+5.5%
3 months+25.5%
1 year+43.1%
3 yearsper year+22.0%
5 yearsper year+5.8%
10 yearsper year+10.1%

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BBH
YearReturn barBBH
2026 YTD+36.3%
2025+21.2%
2024−4.3%
2023+3.9%
2022−15.2%
2021+11.8%
2020+22.1%

BBH in the news

BBH Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.37%Last 12 months
Payout per share
$0.96Last 12 months
Last payment
$0.96 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2017–2026

One bar per payment. 9 payments from 2017 to 2026 YTD. Dec 18, 2017 $0.68; Dec 20, 2018 $0.55; Dec 23, 2019 $0.47; Dec 21, 2020 $0.61; Dec 20, 2021 $0.40; Dec 19, 2022 $0.75; Dec 18, 2023 $0.71; Dec 23, 2024 $1.25; Dec 22, 2025 $0.96. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Dec 22, 2025Dec 26, 2025$0.96
Dec 23, 2024Dec 24, 2024$1.25
Dec 18, 2023Dec 22, 2023$0.71
Dec 19, 2022Dec 23, 2022$0.75
Dec 20, 2021Dec 27, 2021$0.40
Dec 21, 2020Dec 28, 2020$0.61
Dec 23, 2019Dec 30, 2019$0.47
Dec 20, 2018Dec 27, 2018$0.55
Dec 18, 2017Dec 22, 2017$0.68
Dec 19, 2016Dec 23, 2016$0.33
Dec 21, 2015Dec 28, 2015$0.34
Dec 23, 2013Dec 30, 2013$0.003

See all 83 payments⁠

$10,000 in BBH 10 years ago paid $662 in dividends.⁠

BBH Risk

Risk pillarB68 out of 100Rank 6 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
17.2%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.99
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−34.6%
Trough Jun 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.49
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

BBH Cost

Compare BBH and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$3,174

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BBH 0.35%

    $7,126

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • BBH 0.35%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K051015202530BBH $7,126IBBQ $3,952

Year by year

YearBBHIBBQOverpaying
10$634$347$287
20$2,454$1,351$1,103
30$7,126$3,952$3,174

Other funds in Biotech & Genomics

See others